Blocking lipid synthesis induces DNA damage in prostate cancer and increases cell death caused by PARP inhibition.
Androgen deprivation therapy (ADT) is the primary treatment for prostate cancer; however, resistance to ADT invariably develops, leading to castration-resistant prostate cancer (CRPC). Prostate cancer progression is marked by increased de novo synthesis of …